Education and Training
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
- drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
Eligibility
Inclusion Criteria:
- Diagnosis of acute myeloid leukemia by immunophenotyping, morphology, and cytochemical
staining; myelodysplasia; or biphenotypic leukemia.
- Age less than or equal to 21 years at time of study entry.
- No prior therapy for this malignancy (patients with secondary AML following treatment
of primary malignancy are eligible) except for one dose of intrathecal therapy.
- Negative pregnancy test
- Patient does not have Down syndrome, acute promyelocytic leukemia (APL), or juvenile
myelomonocytic leukemia (JMML)
Exclusion Criteria:
- Positive pregnancy test
- Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia
(JMML)
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
LPCH New Patient Coordinator
6507251072
Not Recruiting